具有异常形态特征的肾细胞癌:新一代测序在鉴别肾细胞肿瘤中的临床应用。

IF 1.4 Q3 UROLOGY & NEPHROLOGY
American journal of clinical and experimental urology Pub Date : 2025-08-15 eCollection Date: 2025-01-01 DOI:10.62347/EGWC8899
Jennifer Lee, Xiuping Yu, Yunshin A Yeh
{"title":"具有异常形态特征的肾细胞癌:新一代测序在鉴别肾细胞肿瘤中的临床应用。","authors":"Jennifer Lee, Xiuping Yu, Yunshin A Yeh","doi":"10.62347/EGWC8899","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Clear cell and papillary renal cell carcinomas (RCC) are the two most common RCC subtypes, accounting for approximately 70% and 15% of kidney cancers, respectively. Clear cell RCC is commonly associated with <i>VHL</i> alterations, while papillary RCC typically exhibits chromosomal abnormalities such as +7, +17, and -Y. Furthermore, clear cell RCCs are less likely to exhibit <i>PBRM1</i> and <i>SETD2</i> alterations. This study aims to improve the accuracy of RCC diagnosis by investigating molecular alterations in RCC cases with clear cells, papillary structures, and other atypical histological features.</p><p><strong>Methods: </strong>Nine RCC cases were retrospectively selected and analyzed using histologic slides and immunohistochemical staining for CAIX, RCC, CD10, CK7, P504S, Vimentin, and EMA. Next-generation sequencing was performed on all cases to identify genetic mutations, and cytogenetic analysis was conducted on one case.</p><p><strong>Results: </strong>The cohort consisted of nine male patients aged 49 to 68 years (mean 61.4). Surgical specimens included six radical and three partial nephrectomies; seven tumors were located in the left kidney and two in the right. Tumor sizes ranged from 0.8 to 15.2 cm. Immunohistochemical analysis revealed positive staining for RCC (6/9), CAIX (3/4), CD10 (6/6), and CK7 (5/9). In six clear cell RCCs, next-generation sequencing identified <i>VHL</i> mutations in four tumors, <i>PBRM1</i> alterations in three, and <i>SETD2</i> mutations in one. Five tumors with papillary fronds, sarcomatous components, or unclassified features harboring <i>VHL</i>, <i>PBRM1</i>, and/or <i>SETD2</i> mutations were reclassified as clear cell RCC. One clear cell RCC with leiomyomatous stroma showed <i>mTOR</i> mutations. A case of clear cell papillary renal cell neoplasm showed no reportable gene mutations. The role of a <i>FANCA</i> mutation in one papillary RCC remains uncertain. Cytogenetic analysis of one case (Case #5) revealed 50, X, -Y, +3, +7, +16, +17, +20, consistent with papillary RCC.</p><p><strong>Conclusions: </strong>Next-generation sequencing is a useful method for categorizing RCCs with clear cells, papillary features, and unusual histology. Additionally, <i>VHL</i> mutations could be a promising target for personalized treatment in clear cell RCCs and their histologic variants.</p>","PeriodicalId":7438,"journal":{"name":"American journal of clinical and experimental urology","volume":"13 4","pages":"284-293"},"PeriodicalIF":1.4000,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12444386/pdf/","citationCount":"0","resultStr":"{\"title\":\"Renal cell carcinoma with unusual morphological features: the clinical utility of next-generation sequencing in distinguishing renal cell tumors.\",\"authors\":\"Jennifer Lee, Xiuping Yu, Yunshin A Yeh\",\"doi\":\"10.62347/EGWC8899\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>Clear cell and papillary renal cell carcinomas (RCC) are the two most common RCC subtypes, accounting for approximately 70% and 15% of kidney cancers, respectively. Clear cell RCC is commonly associated with <i>VHL</i> alterations, while papillary RCC typically exhibits chromosomal abnormalities such as +7, +17, and -Y. Furthermore, clear cell RCCs are less likely to exhibit <i>PBRM1</i> and <i>SETD2</i> alterations. This study aims to improve the accuracy of RCC diagnosis by investigating molecular alterations in RCC cases with clear cells, papillary structures, and other atypical histological features.</p><p><strong>Methods: </strong>Nine RCC cases were retrospectively selected and analyzed using histologic slides and immunohistochemical staining for CAIX, RCC, CD10, CK7, P504S, Vimentin, and EMA. Next-generation sequencing was performed on all cases to identify genetic mutations, and cytogenetic analysis was conducted on one case.</p><p><strong>Results: </strong>The cohort consisted of nine male patients aged 49 to 68 years (mean 61.4). Surgical specimens included six radical and three partial nephrectomies; seven tumors were located in the left kidney and two in the right. Tumor sizes ranged from 0.8 to 15.2 cm. Immunohistochemical analysis revealed positive staining for RCC (6/9), CAIX (3/4), CD10 (6/6), and CK7 (5/9). In six clear cell RCCs, next-generation sequencing identified <i>VHL</i> mutations in four tumors, <i>PBRM1</i> alterations in three, and <i>SETD2</i> mutations in one. Five tumors with papillary fronds, sarcomatous components, or unclassified features harboring <i>VHL</i>, <i>PBRM1</i>, and/or <i>SETD2</i> mutations were reclassified as clear cell RCC. One clear cell RCC with leiomyomatous stroma showed <i>mTOR</i> mutations. A case of clear cell papillary renal cell neoplasm showed no reportable gene mutations. The role of a <i>FANCA</i> mutation in one papillary RCC remains uncertain. Cytogenetic analysis of one case (Case #5) revealed 50, X, -Y, +3, +7, +16, +17, +20, consistent with papillary RCC.</p><p><strong>Conclusions: </strong>Next-generation sequencing is a useful method for categorizing RCCs with clear cells, papillary features, and unusual histology. Additionally, <i>VHL</i> mutations could be a promising target for personalized treatment in clear cell RCCs and their histologic variants.</p>\",\"PeriodicalId\":7438,\"journal\":{\"name\":\"American journal of clinical and experimental urology\",\"volume\":\"13 4\",\"pages\":\"284-293\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2025-08-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12444386/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American journal of clinical and experimental urology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.62347/EGWC8899\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of clinical and experimental urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.62347/EGWC8899","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:透明细胞和乳头状肾细胞癌(RCC)是两种最常见的RCC亚型,分别约占肾癌的70%和15%。透明细胞RCC通常与VHL改变相关,而乳头状RCC通常表现为染色体异常,如+7、+17和-Y。此外,透明细胞rcc不太可能表现出PBRM1和SETD2的改变。本研究旨在通过研究具有透明细胞、乳头状结构和其他非典型组织学特征的RCC病例的分子改变来提高RCC诊断的准确性。方法:回顾性选择9例RCC病例,采用组织切片和免疫组化染色对CAIX、RCC、CD10、CK7、P504S、Vimentin、EMA进行分析。对所有病例进行新一代测序以确定基因突变,并对1例进行细胞遗传学分析。结果:该队列包括9例男性患者,年龄49 - 68岁(平均61.4岁)。手术标本包括6例根治性和3例部分性肾切除术;7个肿瘤位于左肾,2个位于右肾。肿瘤大小为0.8 ~ 15.2 cm。免疫组化分析显示RCC(6/9)、CAIX(3/4)、CD10(6/6)和CK7(5/9)染色阳性。在6个透明细胞rcc中,下一代测序在4个肿瘤中发现了VHL突变,3个肿瘤中发现了PBRM1突变,1个肿瘤中发现了SETD2突变。5个具有乳头状叶、肉瘤成分或未分类特征的肿瘤,包含VHL、PBRM1和/或SETD2突变,被重新分类为透明细胞RCC。一例平滑肌瘤基质的透明细胞RCC显示mTOR突变。一例透明细胞乳头状肾细胞瘤未见基因突变。FANCA突变在一个乳头状RCC中的作用仍不确定。1例(病例#5)细胞遗传学分析显示50,X, -Y, +3, +7, +16, +17, +20,与乳头状RCC一致。结论:新一代测序是分类具有透明细胞、乳头状特征和异常组织学的rcc的有效方法。此外,VHL突变可能是透明细胞rcc及其组织学变异个体化治疗的一个有希望的靶点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Renal cell carcinoma with unusual morphological features: the clinical utility of next-generation sequencing in distinguishing renal cell tumors.

Objectives: Clear cell and papillary renal cell carcinomas (RCC) are the two most common RCC subtypes, accounting for approximately 70% and 15% of kidney cancers, respectively. Clear cell RCC is commonly associated with VHL alterations, while papillary RCC typically exhibits chromosomal abnormalities such as +7, +17, and -Y. Furthermore, clear cell RCCs are less likely to exhibit PBRM1 and SETD2 alterations. This study aims to improve the accuracy of RCC diagnosis by investigating molecular alterations in RCC cases with clear cells, papillary structures, and other atypical histological features.

Methods: Nine RCC cases were retrospectively selected and analyzed using histologic slides and immunohistochemical staining for CAIX, RCC, CD10, CK7, P504S, Vimentin, and EMA. Next-generation sequencing was performed on all cases to identify genetic mutations, and cytogenetic analysis was conducted on one case.

Results: The cohort consisted of nine male patients aged 49 to 68 years (mean 61.4). Surgical specimens included six radical and three partial nephrectomies; seven tumors were located in the left kidney and two in the right. Tumor sizes ranged from 0.8 to 15.2 cm. Immunohistochemical analysis revealed positive staining for RCC (6/9), CAIX (3/4), CD10 (6/6), and CK7 (5/9). In six clear cell RCCs, next-generation sequencing identified VHL mutations in four tumors, PBRM1 alterations in three, and SETD2 mutations in one. Five tumors with papillary fronds, sarcomatous components, or unclassified features harboring VHL, PBRM1, and/or SETD2 mutations were reclassified as clear cell RCC. One clear cell RCC with leiomyomatous stroma showed mTOR mutations. A case of clear cell papillary renal cell neoplasm showed no reportable gene mutations. The role of a FANCA mutation in one papillary RCC remains uncertain. Cytogenetic analysis of one case (Case #5) revealed 50, X, -Y, +3, +7, +16, +17, +20, consistent with papillary RCC.

Conclusions: Next-generation sequencing is a useful method for categorizing RCCs with clear cells, papillary features, and unusual histology. Additionally, VHL mutations could be a promising target for personalized treatment in clear cell RCCs and their histologic variants.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
8.30%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信